Skip to main content
. Author manuscript; available in PMC: 2012 Aug 4.
Published in final edited form as: Int J Cardiol. 2010 May 15;150(3):264–269. doi: 10.1016/j.ijcard.2010.04.021

Figure 1. Survival analysis using Kaplan Meier curves comparing digoxin use with placebo.

Figure 1

Figure 1

A. All cause mortality in the digoxin and placebo treatment groups. Left panel represents the Kaplan Meier 1-survival curves for all cause mortality among clusters of patients with no significant association of digoxin with mortality (MortalitydigHR-NS). Right panel represents the Kaplan Meier 1-survival curves for all cause mortality among clusters of patients with a significant increase in mortality with the use of digoxin (MortalitydigHR>1). B. Incidence of hospitalization due to worsening HF (HF Admission) in the digoxin and placebo groups. Left panel represents the Kaplan Meier 1-survival curves for hospitalization due to worsening HF among clusters of patients with a significant reduction in HF hospitalization with the use of digoxin (HFAdigHR<1). Right panel represents the Kaplan Meier 1-survival curves for hospitalization due to worsening HF among clusters of patients with no significant association of digoxin with HF hospitalization (HFAdigHR-NS).